Will Battershill and Hollie Wheat from Delta Hat discuss key insights into HTA decision-making from ISPOR Europe. Will explores the hot topic of incorporating patient and carer perspectives into decision-making, whilst Hollie dives into the use of surrogate endpoint evaluation in HTA decision-making.
Are you unsure about some of the terminology used by specialists who are preparing your evidence dossier? Here our experts answer some of the most frequently asked questions about systematic literature reviews and network meta-analysis.
What is the EU Joint Clinical Assessment (JCA) and what does it mean for market access and reimbursment in Euorpe?
Louise Maddison (Senior Consultant – Global Market Access, Mtech Access) explores the evolving market access landscape for AI-enabled Medtech, with a particular focus on the key European markets of France, Germany and the UK.
What is IDAP? As the IDAP pilot opens, we explore how this new pathway offers a fast-track route to patient access for innovative medical technologies.
Calum Jones (Associate Director – Health Economics) shares his experience speaking at the 2024 HTAi Conference. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economic Evaluations’.
Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US and highlight important considerations for companies seeking to infiltrate this key market.
We bring together specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024-25. Jump in, as our experts give their hot-take on each trend, sharing their perspectives on what’s happening in these areas.
© 2024 Mtech Access. All rights reserved. Privacy policy. Cookie Settings. Sitemap